Journal of Urologic Oncology

Editorial

July 31, 2023

This Month’s Issue of JUO

Cheol Kwak

J Urol Oncol. 2023;21(2):95-96.

Invited Review

July 31, 2023

The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance

Chang Wook Jeong

J Urol Oncol. 2023;21(2):97-105.

This review explores the role of magnetic resonance imaging (MRI) and MRI-targeted biopsies in the selection and monitoring of men with low-risk prostate cancer (PCa) who are on active surveillance...

Invited Review

July 31, 2023

Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use

Byung Kwan Park

J Urol Oncol. 2023;21(2):106-111.

The Prostate Imaging and Reporting and Data System version 2.1 (PI-RADSv2.1) is commonly utilized in interpreting magnetic resonance imaging (MRI) scans in men with elevated prostate-specific antigen levels. This system...

Topic Article

July 31, 2023

Impact of Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Extension According to the National Comprehensive Cancer Network Risk Stratification in Prostate Cancer

Jae Hoon Kang, Jun-Koo Kang, Jae-Wook Chung, et al.

J Urol Oncol. 2023;21(2):112-120.

Purpose: The accuracy of extraprostatic extension (EPE) on multiparametric magnetic resonance imaging (mpMRI) for the preoperative staging of prostate cancer (PCa) remains controversial. This study aimed to determine the effect...

Original Article

July 31, 2023

A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening

Jung Sik Huh, Kyung Kgi Park

J Urol Oncol. 2023;21(2):121-127.

Purpose: : This study aimed to compare the cost-effectiveness and feasibility of biparametric magnetic resonance imaging (bp MRI) for prostate cancer screening to prostate-specific antigen (PSA)-based screening. Materials and Methods: We...

Invited Review

July 31, 2023

Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer

Hyunho Han, Minyong Kang, Seok-Soo Byun, et al.

J Urol Oncol. 2023;21(2):128-139.

As genetic testing plays an increasingly salient role in the realm of cancer diagnosis, prognostication, and treatment, this review aims to elucidate the current landscape and future directions of genetic...

Invited Review

July 31, 2023

Korean Urologic Oncology Society Guidelines: Does Angioembolization Improve the Quality of Life for Renal Cell Carcinoma Patients With Intractable Symptoms Who Are Unfit for Surgery?

Ja Yoon Ku, Hui Mo Gu, Seong Hyeon Yu, et al.

J Urol Oncol. 2023;21(2):140-147.

Purpose: There is a lack of guidelines for using angioembolization to manage renal cell carcinoma (RCC) patients with intractable symptoms. Therefore, the Korean Urologic Oncology Society (KUOS) developed a set...

Original Article

July 31, 2023

Efficacy of Partial Nephrectomy in the Management of Unpredicted pT3a Renal Cell Carcinoma

Dongsu Kim, Bumjin Lim, Jungyo Suh, et al.

J Urol Oncol. 2023;21(2):148-153.

Purpose: To compare the oncological outcomes between patients with pathologic T3a (pT3a) renal cell carcinoma (RCC) who underwent partial nephrectomy (PN) and radical nephrectomy (RN). Materials and Methods: We retrospectively reviewed...

Invited Review

July 31, 2023

The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials

Sang Hun Song, Jong Jin Oh

J Urol Oncol. 2023;21(2):154-164.

Traditional cisplatin-based chemotherapy has long been the mainstay treatment for advanced urothelial carcinoma (UC), but the emergence of immune checkpoint inhibitors (ICIs) and immunotherapy has revolutionized the field. ICIs, which...

Original Article

July 31, 2023

Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis

Youngheun Jo, Jun Seok Kim, Yoo Sub Shin, et al.

J Urol Oncol. 2023;21(2):165-173.

Purpose: Although radical cystectomy (RC) and concurrent chemoradiotherapy (CCRT) are curative options for muscle-invasive bladder cancer (MIBC), the optimal treatment strategy for MIBC patients with a history of nephroureterectomy for...

Original Article

July 31, 2023

The Predictive Value of the Preoperative Systemic Inflammatory Response Indices in Non–Organ-Confined Disease in Upper Urinary Tract Urothelial Carcinoma

Sung Kyung Choi, Chan Hoon Gwak, Jungyo Suh, et al.

J Urol Oncol. 2023;21(2):174-180.

Purpose: This study aims to evaluate the systemic inflammatory response indices (SII) for the prediction of the non–organ-confined (non-OC) disease in upper urinary tract urothelial carcinoma (UTUC) patients. Materials and Methods:...

This Month’s Issue of JUO Cheol Kwak J Urol Oncol. 2023;21(2):95-96. Editorial Jul 31, 2023 Full text PubReader ePub PDF	The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance Chang Wook Jeong J Urol Oncol. 2023;21(2):97-105. Cited By 1 Invited Review Jul 31, 2023 mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness Full text PubReader ePub PDF
Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use Byung Kwan Park J Urol Oncol. 2023;21(2):106-111. Cited By 1 Invited Review Jul 31, 2023 mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness Full text PubReader ePub PDF	Impact of Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Extension According to the National Comprehensive Cancer Network Risk Stratification in Prostate Cancer Jae Hoon Kang, Jun-Koo Kang, Jae-Wook Chung, et al. J Urol Oncol. 2023;21(2):112-120. Cited By 1 Topic Article Jul 31, 2023 mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness Full text PubReader ePub PDF Supplementary Material
A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening Jung Sik Huh, Kyung Kgi Park J Urol Oncol. 2023;21(2):121-127. Cited By 1 Original Article Jul 31, 2023 mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness Full text PubReader ePub PDF	Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer Hyunho Han, Minyong Kang, Seok-Soo Byun, et al. J Urol Oncol. 2023;21(2):128-139. Cited By 1 Invited Review Jul 31, 2023 Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma Full text PubReader ePub PDF
Korean Urologic Oncology Society Guidelines: Does Angioembolization Improve the Quality of Life for Renal Cell Carcinoma Patients With Intractable Symptoms Who Are Unfit for Surgery? Ja Yoon Ku, Hui Mo Gu, Seong Hyeon Yu, et al. J Urol Oncol. 2023;21(2):140-147. Cited By 1 Invited Review Jul 31, 2023 Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma Full text PubReader ePub PDF Supplementary Material	Efficacy of Partial Nephrectomy in the Management of Unpredicted pT3a Renal Cell Carcinoma Dongsu Kim, Bumjin Lim, Jungyo Suh, et al. J Urol Oncol. 2023;21(2):148-153. Cited By 1 Original Article Jul 31, 2023 Genetic Testing and Nonsurgical Management for Renal Cell Carcinoma Full text PubReader ePub PDF
The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials Sang Hun Song, Jong Jin Oh J Urol Oncol. 2023;21(2):154-164. Cited By 1 Invited Review Jul 31, 2023 Trimodality Therapy and Immuno-Oncology for Bladder Cancer Full text PubReader ePub PDF	Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis Youngheun Jo, Jun Seok Kim, Yoo Sub Shin, et al. J Urol Oncol. 2023;21(2):165-173. Cited By 1 Original Article Jul 31, 2023 Trimodality Therapy and Immuno-Oncology for Bladder Cancer Full text PubReader ePub PDF Supplementary Material
The Predictive Value of the Preoperative Systemic Inflammatory Response Indices in Non–Organ-Confined Disease in Upper Urinary Tract Urothelial Carcinoma Sung Kyung Choi, Chan Hoon Gwak, Jungyo Suh, et al. J Urol Oncol. 2023;21(2):174-180. Cited By 1 Original Article Jul 31, 2023 Trimodality Therapy and Immuno-Oncology for Bladder Cancer Full text PubReader ePub PDF

4,034	Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer
3,919	Understanding Cancer Pain and Controlling Pain: Focusing on Patients With Metastatic Urologic Cancer
3,751	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
3,680	Laparoscopic Radical Cystectomy With Intracorporeal Orthotopic Neobladder Reconstruction: An Initial Experience of Modified Studer Reconstruction Techniques
3,659	Expert Group Consensus Opinion on Prostate Cancer Diagnosis and Management in India: Part 2 of 2

Cited By 1	Understanding Cancer Pain and Controlling Pain: Focusing on Patients With Metastatic Urologic Cancer
Cited By 1	The Effects of Recombinant Bacillus Calmette-Guérin Resistant to Antimicrobial Peptides on Orthotopic Bladder Cancer Mouse Model
Cited By 1	Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer
Cited By 1	Predictive Factors of De Novo Overactive Bladder After Radical Prostatectomy in Patients With Clinically Localized Prostate Cancer: A Prospective Observational Study
Cited By 1	Investigation of Information Acquisition Channel for Prostate Cancer High-Risk Group